Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care (NASDAQ: TNDM) announced a company update presentation scheduled for May 10, 2023, at 4:40 PM Eastern Time during the BofA Securities 2023 Health Care Conference. The live event will be accessible via webcast, with an archive available for 30 days afterward.

The presentation will highlight Tandem's commitment to innovation in insulin delivery and diabetes technology, emphasizing their human-centered design approach. The company manufactures the t:slim X2 insulin pump featuring Control-IQ technology, aimed at enhancing the management of diabetes for users and healthcare providers.

For more details, the webcast link can be found on Tandem’s Investor Center website under the “Events & Presentations” section.

Tandem Diabetes Care (NASDAQ: TNDM) announced a publication in Diabetes Technology & Therapeutics of a meta-analysis from three randomized controlled trials showcasing its Control-IQ advanced hybrid closed-loop technology. The study highlights significant improvements in glucose control, with an average increase in time in range of 2.8 hours and a reduction in hemoglobin A1c levels across diverse demographics, including ages 2 to 72. Those with the highest baseline blood sugar benefited most from the automatic correction bolusing feature. The results indicate broad applicability of Control-IQ technology, enhancing diabetes management effectiveness. Notably, the technology's comprehensive data set supports its advantages over competing automated insulin delivery systems.

Tandem Diabetes Care plans to release its first quarter 2023 results on May 3, 2023, after market close. A conference call will take place at 4:30 PM ET to discuss financial and operating results. Investors can access the live webcast on the company's Investor Center website. The event will provide insights into the company's performance, focusing on innovative diabetes technology products such as the t:slim X2 insulin pump with Control-IQ technology. Tandem Diabetes Care aims to enhance the experience for individuals managing diabetes through its human-centered approach.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced favorable results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial, published in the New England Journal of Medicine. Children aged 2-5 using the t:slim X2 insulin pump with Control-IQ technology experienced an approximate 3-hour daily increase in time in range compared to standard insulin treatments. Key findings showed a 12.4% adjusted mean difference in time in range and a 0.5% decrease in Hemoglobin A1c levels. The trial included 101 participants, with 94% system usability, indicating significant improvements in glucose control.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has appointed Rebecca Robertson as Chair of its Board of Directors, effective immediately. Ms. Robertson, who joined the Board in January 2019, takes over from Kim Blickenstaff, who remains a Board member. The transition comes as the company seeks to enhance its leadership during a pivotal growth phase. CEO John Sheridan and Blickenstaff praised Robertson for her valuable insights and experience in medical devices. With a strong background in scaling medical companies, Robertson expressed her commitment to advancing Tandem's innovative solutions for diabetes care. The company continues to develop a promising product pipeline.

Tandem Diabetes Care (NASDAQ: TNDM) announced its financial results for Q4 and the full year 2022, highlighting a 14% increase in worldwide GAAP sales to $801.2 million and a 15% increase in non-GAAP sales to $804.8 million. The company reported a 29% growth in its customer base, totaling approximately 420,000. However, a GAAP operating loss of $92.8 million was noted for the year. In terms of guidance for 2023, TNDM expects non-GAAP sales between $885 million and $900 million, representing a growth of 10-12%. The firm also acquired AMF Medical SA, enhancing its product portfolio.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in several upcoming investor conferences. Key presentations will take place at the Citi Healthcare Services Conference on March 2, Cowen Healthcare Conference on March 6, Raymond James Conference on March 8, Oppenheimer Healthcare Conference on March 13, and Barclays Global Healthcare Conference on March 14. Each presentation will be webcast live, with an archive available for 30 days on their Investor Center website. Tandem Diabetes focuses on innovative insulin delivery solutions, including the t:slim X2 insulin pump.

Tandem Diabetes Care (NASDAQ:TNDM) has completed its acquisition of AMF Medical SA, the Swiss developer of the Sigi™ Patch Pump, which focuses on simplifying diabetes management. The Sigi Patch Pump is still under development and not yet commercially available. The acquisition aligns with Tandem's strategy to enhance its product offerings, bringing in AMF's innovative technology and experienced team. With a mission to improve diabetes care, Tandem aims to leverage this technology to better serve its customers.